GLPBio

Signaling Pathways

Research Area, Signaling Pathways | GlpBio Life Science Products Suppliers

Read More about this category

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. The three components of the ADC together give rise to a powerful oncolytic agent capable of delivering normally intolerable cytotoxins directly to cancer cells, which then internalize and release the cell-destroying drugs. At present, two ADCs, Adcetris and Kadcyla, have received regulatory approval with >40 others in clinical development.

ADCs are administered intravenously in order to prevent the mAb from being destroyed by gastric acids and proteolytic enzymes. The mAb component of the ADC enables it to circulate in the bloodstream until it finds and binds to tumor-specific cell surface antigens present on target cancer cells. Linker chemistry is an important determinant of the safety, specificity, potency and activity of ADCs. Linkers are designed to be stable in the blood stream (to conform to the increased circulation time of mAbs) and labile at the cancer site to allow rapid release of the cytotoxic drug. First generation ADCs made use of early cytotoxins such as the anthracycline, doxorubicin or the anti-metabolite/antifolate agent, methotrexate. Current cytotoxins have far greater potency and can be divided into three main groups: auristatins, maytansines and calicheamicins.

The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.

References:

[1] Tsuchikama K, et al. Protein Cell. 2016 Oct 14. DOI:10.1007/s13238-016-0323-0.

[2] Peters C, et al. Biosci Rep. 2015 Jun 12;35(4). pii: e00225. doi: 10.1042/BSR20150089.

Research Areas

Products Related to Signaling Pathways(40938)

  • GC81423 structure
    GC81423MRG004A Antibody
    Purity: >95.00%

    MRG004A Antibody (HuSC1-39) is a monoclonal antibody inhibitor targeting tissue factor (TF).

  • GC81424 structure
    GC81424OMTX005
    Purity: >98.00%

    OMTX005 (OMTX705 antibody) is a humanized anti- FAP IgG1 monoclonal antibody that specifically binds to human ( EC 50: 0.33 nM)/mouse ( EC 50: 0.14 nM) FAP proteins and FAP-positive cells.

  • GC81425 structure
    GC81425Sutantatug
    CAS: 3049680-24-9
    Purity: >99.50%

    Sutantatug (SYS6002 Antibody) is a monoclonal antibody targeting Nectin-4, and serves as the antibody moiety of the ADC CRB-701.

  • GC81426 structure
    GC81426EBC-129 Antibody
    Purity: >99.00%

    EBC-129 Antibody is a specific antibody for the synthetic antibody-drug conjugate (ADC) EBC-129, which specifically targets CEACAM5 and CEACAM6 glycosylated at N256.

  • GC81427 structure
    GC81427Zevontabart
    CAS: 3060218-90-5
    Purity: >99.00%

    Zevontabart (MYTX-011 Antibody; Q-397) is a pH-dependent anti- c-MET antibody.

  • GC81428 structure
    GC81428Rolditamig
    CAS: 3038136-62-5
    Purity: >95.00%

    Rolditamig (TQB2102 Antibody) is a recombinant humanized anti-human epidermal growth factor receptor 2 ( HER2 ) antibody.

  • GC81429 structure
    GC81429Mansonone E
    CAS: 81845-40-1
    Purity: >99.00%

    Mansonone E (Compound 5) is a pesticide.

  • GC81430 structure
    GC814303-Hydroxyindole
    CAS: 480-93-3
    Purity: >87.50%

    3-Hydroxyindole is a hydroxyindole compound.

  • GC81431 structure
    GC81431(S,S,S)-Icafolin-methyl
    CAS: 2254813-53-9
    Purity: >99.50%

    (S,S,S)-Icafolin-methyl is an isomer of Icafolin-methyl.

  • GC81432 structure
    GC81432ART5537
    Purity: >99.50%

    ART5537 is a selective EXO1 inhibitor with a IC 50 of 3.4 nM and a K d of 6.8 nM.

  • GC81433 structure
    GC81433PEN (human) TFA
    Purity: >97.00%

    PEN (human) TFA, one of the most abundant hypothalamic neuropeptide and derived from the proprotein ProSAAS, is an endogenous ligand of GPR83 [1] .

  • GC81434 structure
    GC81434RAS activator compound 1
    CAS: 1579978-17-8
    Purity: >98.50%

    RAS activator compound 1 (Compound 7c) is a RAS activator targeting the guanine nucleotide exchange factor (GEF) son of sevenless homologue 1 ( SOS1 ).

  • GC81435 structure
    GC814352-Bromo-LSD D-Tartrate
    CAS: 2855123-30-5
    Purity: >99.50%

    2-Bromo-LSD D-Tartrate (BOL-148 D-Tartrate) is a blood-brain barrier-permeable 5-HT 2A partial agonist and competitive partial antagonist.

  • GC81436 structure
    GC81436Renditatug
    CAS: 3037073-23-4
    Purity: >99.50%

    Renditatug (BAT8008 Antibody) is an antibody targeting TROP2.

  • GC81437 structure
    GC81437Avenanthramide 1c
    CAS: 116764-16-0
    Purity: >98.00%

    Avenanthramide 1c is a free radical scavenger and antioxidant.

  • GC81438 structure
    GC81438Tyrosinase-IN-50
    CAS: 3081328-14-2
    Purity: >99.50%

    Tyrosinase-IN-50 (Compound 14) is a Tyrosinase inhibitor ( IC 50 is 0.06 μM or 0.16 μM).

  • GC81439 structure
    GC81439SZ0232
    CAS: 924851-91-2
    Purity: >99.00%

    SZ0232 is a selective mPGES-2 inhibitor.

  • GC81440 structure
    GC81440Luteolin 7-O-(6-O-malonyl-β-D-glucoside)
    CAS: 98767-38-5
    Purity: >98.00%

    Luteolin 7-O-(6-O-malonyl-β-D-glucoside) is an orally active flavonoid free radical scavenger.

  • GC81441 structure
    GC81441Butyl caffeate
    CAS: 22020-28-6
    Purity: >98.00%

    Butyl caffeate (Caffeic acid butyl ester) is a caffeic acid derivative with antioxidant activity and lipophilicity ( DPPH IC 50 = 14.1 μM).

  • GC81442 structure
    GC81442Creatine transporter-IN-1
    CAS: 1706435-74-6
    Purity: >98.00%

    Creatine transporter-IN-1 is a synthetic creatine transporter ( CT1/SLC6A8 ) inhibitor.

  • GC81443 structure
    GC81443E8431
    CAS: 2419580-01-9
    Purity: >97.00%

    E8431 is a DCSTAMP antagonist with an IC 50 value of 775.8 nM for osteoclastogenesis.

  • GC81444 structure
    GC81444SLC6A19-IN-4
    CAS: 2962069-39-0
    Purity: >99.50%

    SLC6A19-IN-4 is an allosteric-competitive and orally active B 0 AT1 inhibitor.

  • GC81445 structure
    GC81445S-Adenosyl-3-thiopropylamine
    CAS: 53186-57-5
    Purity: >98.00%

    S-Adenosyl-3-thiopropylamine acts as a weak to moderate reversible inhibitor of spermidine/spermine synthase, and its inhibitory activity increases after oxidation (to S-Adenosyl-3-thiopropylamine sulphoxide and S-Adenosyl-3-thiopropylamine sulphone) [1] .

  • GC81446 structure
    GC81446ARF(26-44), cell-permeable acetate
    Purity: >99.00%

    ARF(26-44), cell-permeable acetate is a cell-penetrating peptide derived from a specific amino acid sequence of the p14ARF tumor suppressor protein.